A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes

International Journal of Cardiology

Volumn 183, Issue , 2015, Pages 47-53

  Marenzi, Giancarlo ^a   Cosentino, Nicola ^a   Werba, José P ^a   Tedesco, Calogero C ^a   Veglia, Fabrizio ^a   Bartorelli, Antonio L ^a,b  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute coronary syndromes; Contrast induced acute kidney injury; Coronary angiography; Percutaneous coronary intervention; Statins

Indexed keywords

ACETYLCYSTEINE; ATORVASTATIN; CONTRAST MEDIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IOBITRIDOL; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ANGIOCARDIOGRAPHY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HUMAN; LOW DRUG DOSE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RISK REDUCTION; SHORT COURSE THERAPY; ACUTE KIDNEY INJURY; AGED; COMPLICATION; FEMALE; MALE; MIDDLE AGED;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY INJURY; AGED; CONTRAST MEDIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84924937723     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.01.046     Document Type: Article

References (45)

1. P.A. McCullough Contrast-induced acute kidney injury J. Am. Coll. Cardiol. 51 2008 1419 1428
2. S.D. Weisbord, and P.M. Palevsky Contrast-induced acute kidney injury: short and long-term implications Semin. Nephrol. 31 2011 300 309
3. Task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial revascularization Eur. Heart J. 31 2010 2501 2555
4. Y. Han, G. Zhu, and L. Han et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease J. Am. Coll. Cardiol. 63 2014 62 70
5. C. Quintavalle, D. Fiore, and F. De Micco et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury Circulation 126 2012 3008 3016
6. S. Acikel, H. Muderrisoglu, and A. Yildirir et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography Blood Coagul. Fibrinolysis 21 2010 750 757
7. S. Khanal, N. Attallah, and D.E. Smith et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions Am. J. Med. 118 2005 843 849
8. B.C. Zhang, W.M. Li, and Y.W. Xu High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis Can. J. Cardiol. 27 2011 851 858
9. A. Toso, M. Maioli, and M. Leoncini et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease Am. J. Cardiol. 105 2010 288 292
10. H. Ozhan, I. Erden, and S. Ordu et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography Angiology 61 2010 711 714
11. S. Han, X.M. Li, L.A. Mohammed Ali, N.K. Fu, D.X. Jin, and H.L. Cong Effect of short-term different statins loading dose on renal function and CI-AKI incidence in patients undergoing invasive coronary procedures Int. J. Cardiol. 168 2013 5101 5103
12. S.H. Jo, B.K. Koo, and J.S. Park et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study Am. Heart J. 155 2008 499.e1 499.e8
13. T. Zhang, L.H. Shen, L.H. Hu, and B. He Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis Am. J. Nephrol. 33 2011 344 351
14. G. Marenzi, G. Lauri, and E. Assanelli et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction J. Am. Coll. Cardiol. 44 2004 1780 1785
15. M. Leoncini, A. Toso, M. Maioli, F. Tropeano, S. Villani, and F. Bellandi Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome. Results from protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS Study) J. Am. Coll. Cardiol. 63 2014 71 79
16. G. Patti, E. Ricottini, and A. Nusca et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial) Am. J. Cardiol. 108 2011 1 7
17. W. Li, X. Fu, and Y. Wang et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention Cardiology 122 2012 195 202
18. J. Xinwei, F. Xianghua, and Z. Jing et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention Am. J. Cardiol. 104 2009 519 524
19. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman For the PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement J. Clin. Epidemiol. 62 2009 1006 1012
20. N. Attallah, L. Yassine, J. Musial, J. Yee, and K. Fisher The potential role of statins in contrast nephropathy Clin. Nephrol. 62 2004 273 278
21. A. Caixeta, and R. Mehran Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury Catheter. Cardiovasc. Interv. 75 Suppl. 1 2010 S15 S20
22. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control. Clin. Trials 7 1986 177 188
23. A. Tobias Assessing the influence of a single study in meta-analysis STB 47 1999 15 17
24. S.J. Sharp Meta-analysis regression STB 42 1998 16 22
25. P. Costanzo, P. Perrone-Filardi, and M. Petretta et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients J. Hypertens. 27 2009 1136 1151
26. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
27. T. Senoo, M. Motohiro, and H. Kamihata et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome Am. J. Cardiol. 105 2010 624 628
28. M.S. Zhou, I.H. Schuman, E.A. Jaimes, and L. Raij Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability Am. J. Physiol. Renal Physiol. 295 2008 F53 F59
29. V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, and G. Di Sciascio Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study Circulation 110 2004 674 678
30. K.H. Yun, M.H. Jeong, and S.K. Oh et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome Int. J. Cardiol. 137 2009 246 251
31. K.H. Yun, S.K. Oh, S.J. Rhee, N.J. Yoo, N.H. Kim, and J.W. Jeong 12-Month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome Int. J. Cardiol. 146 2011 68 72
32. Y. Zhou, W.J. Yuan, N. Zhu, and L. Wang Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis Clin. Nephrol. 76 2011 475 483
33. P. Libby Mechanisms of acute coronary syndromes and their implications for therapy N. Engl. J. Med. 368 2013 2004 2013
34. T. Ichiki, K. Takeda, and T. Tokunou et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells Arterioscler. Thromb. Vasc. Biol. 21 2001 1896 1901
35. O. Hernández-Perera, D. Pérez-Sala, and J. Navarro-Antolín et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells J. Clin. Invest. 101 1998 2711 2719
36. P.O. Bonetti, L.O. Lerman, C. Napoli, and A. Lerman Statin effects beyond lipid lowering - are they clinically relevant? Eur. Heart J. 24 2003 225 248
37. G. Patti, M. Chello, and V. Pasceri et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy J. Am. Coll. Cardiol. 48 2006 1560 1566
38. Y. Rikitake, S. Kawashima, and S. Takeshita et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits Atherosclerosis 154 2001 87 96
39. J.C. Mason, Z. Ahmed, and R. Mankoff et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury Circ. Res. 91 2002 696 703
40. D. Lecian, H. Demova, and A. Lodererova et al. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis Kidney Blood Press. Res. 29 2006 135 143
41. D.H. Walter, S. Fichtlscherer, and M.B. Britten et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation J. Am. Coll. Cardiol. 38 2001 2006 2012
42. S. Zhu, H. Viswambharan, T. Gajanayake, X.F. Ming, and Z. Yang Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells BMC Cardiovasc. Disord. 5 2005 22
43. C. Briguori, A. Colombo, and F. Airoldi et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction Eur. Heart J. 25 2004 1822 1828
44. A. Sciahbasi, F. Andreotti, and R. De Cristofaro et al. Prothrombotic response to coronary angioplasty in patients with unstable angina and raised C-reactive protein J. Thromb. Thrombolysis 14 2002 131 138
45. B.J. Barrett, and P.S. Parfrey Clinical practice. Preventing nephropathy induced by contrast medium N. Engl. J. Med. 354 2006 379 386